BioSpace News Archive

Avenue Therapeutics, Inc. today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock.

InflaRx N.V. today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City.

Endeavor BioMedicines, Inc. today announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument.

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update.

IN8bio, Inc. today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

BriaCell Therapeutics Corp. is pleased to announce an oral presentation on the clinical data of the randomized Phase 2 study evaluating Bria-IMT™ in patients with advanced metastatic breast cancer at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 at McCormick Place, Chicago, IL.

Immutep Limited today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.

Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples.

Oruka Therapeutics, Inc. today announced the strengthening of its leadership team with the addition of two experienced executives.

Valcare Medical, Inc. Announces Corporate Restructuring and Appointment of New CEO.